News Article | May 11, 2017
Veerhouse Voda, often recognized for its robust and disaster resilient housing, emergency structures, and community buildings, recently sealed its partnership with Global Therapy Group on a new rehabilitation center that will serve the needs of the greater Port au Prince area. “Haiti’s need for rehabilitation services existed long before the earthquake,” a representative from Global Therapy Group said. The organization is known for its dedication to people of all ages in need of physical, occupational and speech therapy services, regardless of economic status, age or religion. “Prior to the earthquake, children born with developmental disabilities had never had therapy services to help them reach their full potential. Hypertension, diabetes and strokes have robbed many of productive, meaningful lives. Broken bones from simple accidents have led to unnecessary disability. Global Therapy Group’s vision is to establish permanent rehabilitation clinics located within the communities they serve and managed by Haitian therapy professionals. As part of its commitment to the Haitian people, Global Therapy Group also creates job opportunities for Haitian therapists and provides educational opportunities as well as training to ensure the therapy provided is of the highest quality; on par with current therapy standards around the world. To learn more about why Veerhouse Voda’s disaster resilient housing and community structures are the ideal choice when quality and affordability are paramount, visit VeerhouseVoda.com. The new rehabilitation center will span 767 square meters and feature a large therapy gym, private treatment rooms, a classroom, and other offerings to serve the needs of the local population. In 2010, Global Therapy Group originally focused on injuries sustained by Haitians in the earthquake with treatment provided exclusively by therapy volunteers who traveled from the U.S., Canada and Europe. The organization now has five Haitian employees, including two bachelor’s degree physical therapists, a clinic manager, and two intake coordinators. Additionally, approximately 25 volunteer physical, occupational, and speech therapists from around the world each year are welcomed to its facility to assist and mentor the Haitian staff as well as provide educational opportunities. “We are pleased to be partnering with Global Therapy Group to bring much needed rehabilitation facilities to Haiti,” says Veerhouse Voda’s Brendon Brewster. “This facility will create jobs and improve the lives of those with disabilities. The facility itself will be built with technology that is faster and more energy efficient than traditional structures, and we are pleased to be entrusted by Global Therapy Group with creation of this important facility.” Go to VeerhouseVoda.com to learn more about the company now. In all, the structure is expected to be completed in just 12 weeks, as Veerhouse Voda’s proprietary system is approximately five times faster than traditional building systems. This allows for significant time and cost savings over other conventional construction methods. Moreover, the Veerhouse Voda system has a wide range of uses, can be used on almost any type of commercial or residential development, and is built to Eurocodes standards. Its local presence in Port au Prince ensures rapid response to disasters and Disaster Resilient Housing Maker Veerhouse Voda Partners with Global Therapy Group employs local people, so the power to rebuild and improve the country remains in the hands of Haitians. Global Therapy Group, a 501c3 non-profit organization, has provided rehabilitation services in the Freres/Petionville area since April of 2010. In addition to providing worldclass physical, occupational and speech therapy services to adults and children in the Port au Prince community, the organization has partnerships with several university physical therapy programs in the U.S., including Georgia Regents University, Sargent College, and Mary Baldwin College. The organization will collaborate with the therapy program at the Episcopal University in Leogane, and the soon to be established program at Notre Dame d’Haiti University, to provide a clinical internship site for the students. Global Therapy Group further assists Health Volunteers Overseas in creating employment opportunities for physical therapists within Haiti. Veerhouse Voda LLC is involved in the design, marketing, manufacture, and delivery of sustainable, inexpensive, environmentally friendly, disaster resilient housing and commercial buildings. In Haiti, the company operates as EPS Haiti, with a factory located in Port au Prince. To learn more, go to VeerhouseVoda.com now. For more information, please visit http://www.veerhousevoda.com/
Mei L.,Georgia Regents University |
Mei L.,Charlie Norwood Medical Center |
Nave K.-A.,Max Planck Institute for Experimental Medicine
Neuron | Year: 2014
Neuregulins (NRGs) comprise a large family of growth factors that stimulate ERBB receptor tyrosine kinases. NRGs and their receptors, ERBBs, have been identified as susceptibility genes for diseases such as schizophrenia (SZ) and bipolar disorder. Recent studies have revealed complex Nrg/Erbb signaling networks that regulate the assembly of neural circuitry, myelination, neurotransmission, and synaptic plasticity. Evidence indicates there is an optimal level of NRG/ERBB signaling in the brain and deviation from it impairs brain functions. NRGs/ERBBs and downstream signaling pathways may provide therapeutic targets for specific neuropsychiatric symptoms. Neuregulins (NRGs) comprise a family of growth factors that activate ERBB receptor kinases. Mei and Nave review the role of Nrg-Erbb signaling in neural development, myelination, and synaptic plasticity and the possible contribution of abnormal NRG1 signaling to brain disorders. © 2014 Elsevier Inc.
Yue H.-Y.,Georgia Regents University |
Xu J.,Georgia Regents University
Journal of Neuroscience | Year: 2014
Neuronal activity triggers endocytosis at synaptic terminals to retrieve efficiently the exocytosed vesicle membrane, ensuring the membrane homeostasis of active zones and the continuous supply of releasable vesicles. The kinetics of endocytosis depends on Ca2+ and calmodulin which, as a versatile signal pathway, can activate a broad spectrum of downstream targets, including myosin light chain kinase (MLCK). MLCK is known to regulate vesicle trafficking and synaptic transmission, but whether this kinase regulates vesicle endocytosis at synapses remains elusive. We investigated this issue at the rat calyx of Held synapse, where previous studies using whole-cell membrane capacitance measurement have characterized two common forms of Ca2+/calmodulin-dependent endocytosis, i.e., slow clathrin-dependent endocytosis and rapid endocytosis. Acute inhibition of MLCK with pharmacological agents was found to slow down the kinetics of both slow and rapid forms of endocytosis at calyces. Similar impairment of endocytosis occurred when blocking myosin II, a motor protein that can be phosphorylated upon MLCK activation. The inhibition of endocytosis was not accompanied by a change in Ca2+ channel current. Combined inhibition of MLCK and calmodulin did not induce synergistic inhibition of endocytosis. Together, our results suggest that activation of MLCK accelerates both slow and rapid forms of vesicle endocytosis at nerve terminals, likely by functioning downstream of Ca2+/calmodulin. © 2014 the authors.
Ergul A.,Georgia Regents University
Pharmacological Research | Year: 2011
Diabetes is not only an endocrine but also a vascular disease. Cardiovascular complications are the leading cause of morbidity and mortality associated with diabetes. Diabetes affects both large and small vessels and hence diabetic complications are broadly classified as microvascular (retinopathy, nephropathy and neuropathy) and macrovascular (heart disease, stroke and peripheral arterial disease) complications. Endothelial dysfunction, defined as an imbalance of endothelium-derived vasoconstrictor and vasodilator substances, is a common denominator in the pathogenesis and progression of both macro and microvascular complications. While the pathophysiology of diabetic complications is complex, endothelin-1 (ET-1), a potent vasoconstrictor with proliferative, profibrotic, and proinflammatory properties, may contribute to many facets of diabetic vascular disease. This review will focus on the effects of ET-1 on function and structure of microvessels (retina, skin and mesenteric arteries) and macrovessels (coronary and cerebral arteries) and also discuss the relative role(s) of endothelin A (ET A) and ET B receptors in mediating ET-1 actions. © 2011 Elsevier Ltd. All rights reserved.
Li Y.,Georgia Regents University |
Kim J.,Georgia Regents University
Hippocampus | Year: 2016
The effects of cannabinoids are mostly mediated by two types of cannabinoid receptors-CB1 receptors in the nervous system and CB2 receptors in the immune system. However, CB2 cannabinoid receptors have recently been discovered in the brain and also implicated in neurophysiological functions. The deletion of CB2 receptors in mice induces long-term memory deficits and schizophrenia-like behaviors, implying that endogenous activity of CB2 receptors might be involved in neuropsychiatric effects. Little is known about the cellular mechanisms by which physiological activation of CB2 receptors modulates neuronal functions. We aimed to determine how deletion of CB2 receptors in mice affects synaptic transmission and plasticity. Electrophysiological and morphological studies indicated that CB2 receptor knockout resulted in decreases in excitatory synaptic transmission, long-term potentiation, and dendritic spine density in the hippocampus. Our data imply that endogenous activity of CB2 receptors might contribute to the maintenance of synaptic functions and the expression of normal long-term potentiation. This study provides insights into the role of CB2 cannabinoid receptors in regulating cognitive functions such as long-term memory. © 2016 Wiley Periodicals, Inc.
Flatow J.,Georgia Regents University |
Buckley P.,Georgia Regents University |
Miller B.J.,Georgia Regents University
Biological Psychiatry | Year: 2013
Background Schizophrenia is associated with impaired antioxidant defense, including abnormal serum, plasma, and red blood cell (RBC) oxidative stress parameters. We performed a meta-analysis of these associations, considering the effect of clinical status and antipsychotic treatment after an acute exacerbation of psychosis. Methods We identified articles by searching PubMed, PsychInfo, and Institute for Scientific Information, and the reference lists of identified studies. Results Forty-four studies met the inclusion criteria. Total antioxidant status seemed to be a state marker, because levels were significantly decreased in cross-sectional studies of serum and plasma in first-episode psychosis (FEP) and significantly increased in longitudinal studies of antipsychotic treatment for acute exacerbations of psychosis (p <.01 for each). The RBC catalase and plasma nitrite seemed to be state-related markers, because levels in cross-sectional studies were significantly decreased in FEP (p <.01) and significantly increased in stable outpatients (p =.01). In contrast, RBC superoxide dismutase seemed to be a trait marker for schizophrenia, because levels in cross-sectional studies were significantly decreased in acutely relapsed inpatients, FEP, and stable outpatients (p <.01 for each). Conclusions Oxidative stress abnormalities in FEP suggest an effect that might be independent of antipsychotic medications. Although some parameters (total antioxidant status, RBC catalase, and plasma nitrite) might be state markers for acute exacerbations of psychosis, others (RBC superoxide dismutase) might be trait markers; however, more longitudinal studies are needed. Our findings suggest that oxidative stress might serve as a potential biomarker in the etiopathophysiology and clinical course of schizophrenia. © 2013 Society of Biological Psychiatry.
Pearlman B.L.,Center for Hepatitis C |
Pearlman B.L.,Georgia Regents University
The Lancet Infectious Diseases | Year: 2012
For the past decade, the standard treatment for chronic hepatitis C infection has been pegylated-interferon plus ribavirin. With US Food and Drug Administration approval of boceprevir and telaprevir-two protease inhibitors-the standard-of-care treatment for genotype-1 infection, the main genotype worldwide, is now peginterferon plus ribavirin and a protease inhibitor. Rates of sustained virological response or cure with triple combination treatment have improved substantially, both in patients who have had previous treatment and in those who have not. Improvements have been most substantial in populations regarded as difficult to treat, such as individuals with cirrhosis. However, despite improved response rates, protease inhibitors have incremental toxic effects, high costs, increased pill burden, and many drug interactions. Moreover, because new antiviral drugs directly inhibit hepatitis C virus, viral resistance has become an important issue, essentially precluding use of protease inhibitor monotherapy, and potentially restricting future treatment options for patients who consequently do not achieve sustained virological response. Protease inhibitors are the first of many antiviral medications that will probably be combined in future interferon-free regimens. © 2012 Elsevier Ltd.
Neunert C.E.,Georgia Regents University
Blood | Year: 2013
Long-term follow-up of children with immune thrombocytopenia (ITP) indicates that the majority undergo remission and severe thrombocytopenia is infrequent. Details regarding bleeding manifestations, however, remain poorly categorized. We report here long-term data from the Intercontinental Cooperative ITP Study Group Registry II focusing on natural history, bleeding manifestations, and management. Data on 1345 subjects were collected at diagnosis and at 28 days, 6, 12, and 24 months thereafter. Median platelet counts were 214 × 10(9)/L (interquartile range [IQR] 227, range 1-748), 211 × 10(9)/L (IQR 192, range 1-594), and 215 × 10(9)/L (IQR 198, range 1-598) at 6, 12, and 24 months, respectively, and a platelet count <20 × 10(9)/L was uncommon (7%, 7%, and 4%, respectively). Remission occurred in 37% of patients between 28 days and 6 months, 16% between 6 and 12 months, and 24% between 12 and 24 months. There were no reports of intracranial hemorrhage, and the most common site of bleeding was skin. In patients with severe thrombocytopenia we observed a trend toward more drug treatment with increasing number of bleeding sites. Our data support that ITP is a benign condition for most affected children and that major hemorrhage, even with prolonged severe thrombocytopenia, is rare.
Lambert N.A.,Georgia Regents University
Science Signaling | Year: 2010
G protein-coupled receptors (GPCRs), also known as seven-transmembrane receptors (7TMRs), transduce various sensory and nonsensory signals. It is now widely accepted that these receptors associate with each other as homomeric or heteromeric dimers or as higher-order oligomers. This realization raises a number of questions regarding the quaternary structure of GPCRs and the function of GPCR oligomers: How does ligand binding in one protomer affect an associated protomer? What is the functional unit that activates downstream signaling molecules? What parts of the receptor form the interfaces between protomers? Where along the pathway from synthesis to degradation do oligomers form? Do they ever dissociate? Until recently, this last question has attracted little attention, and GPCR dimers and oligomers have generally been considered to be stable structures. However, biophysical studies have now begun to address this question, and the answer that is emerging will require a reassessment of the stable dimer model. Copyright 2008 the American Association for the Advancement of Science; all rights reserved.
Georgia Regents University, H. Lee Moffitt Cancer Center and Research Institute | Date: 2016-01-11
Methods of treating a disease or disorder characterized by cells with increased or aberrant expression of cytokeratin-8 (CK8) are disclosed. The methods typically include administering to a subject in need thereof a pharmaceutical composition including an effective amount of a CK8 inhibitor. Exemplary diseases include thyroid cancers, particularly thyroid cancers characterized by poorly differentiated or undifferentiated cells. In the most preferred embodiments the cancer is an anaplastic thyroid cancer or a poorly differentiated papillary thyroid cancer. Disclosed inhibitors include, functional nucleic acids, inhibitory anti-CK8 antibodies, inhibitory peptides, and small molecules.